Építés alatt – nem éles oldal
Belépés
Visszavonva2. fázis

Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma

A legfontosabb adatok

Ki végzi
John M. Buatti
Hol
Iowa City (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Fázis
2. fázis
Kezdés
2019. máj. 15.
Várható befejezés
2026. dec. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • External beam radiation therapy
A regiszteradat frissítve
2020. szeptember 9.
Miért állt le
Not funded

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 25 feltétel megnézéseKevesebb

Ki vehet részt

  • Ability to understand and willingness to provide informed consent
  • Newly diagnosed, histologically-confirmed supratentorial WHO grade IV gliomas including glioblastoma (all variants) and gliosarcoma
  • Patients must be 18 years of age or older.≥
  • Karnofsky performance status ≥ 70
  • Minimal life expectancy of 12 weeks
  • Maximal contiguous volume of tumor based on high b-value diffusion MRI and perfusion MRI < 1/3 volume of brain
  • Patients must be treated within 6 weeks of most recent resection; Within 21 days of radiation fraction 1, the following blood test parameters must be met:
  • Hemoglobin ≥ 10 g/dL (transfusion is acceptable)
  • absolute neutrophils ≥ 1500/mm3
  • platelet count ≥ 100,000/mm3
  • total bilirubin ≤ 2 x upper limit of normal (ULN) (unless elevated bilirubin is related to Gilbert syndrome)
  • ALT and AST ≤ 5 x ULN
  • serum creatinine ≤ 2.0 mg/dL

Ki nem vehet részt

  • Recurrent glioma, or tumor involving the brainstem or cerebellum. Prior low-grade glioma without prior RT, now with malignant progression are eligible
  • Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment is not permitted. Prior chemotherapy for a different cancer is allowable if interval since last treatment cycle completion is >3 years
  • Evidence of severe concurrent disease requiring treatment
  • Patients treated with previous cranial or head/neck radiotherapy leading to significant radiation field overlap
  • Pregnant women are excluded from this study because ionizing radiation is a known teratogen, and temozolomide is a Class D agent with the potential for teratogenic or abortifacient effects
  • Nursing mothers declining to discontinue breastfeeding are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with temozolomide
  • Evidence of CSF dissemination (positive CSF cytology for malignancy or MRI findings consistent with CSF dissemination)
  • Multifocal disease (>1 lobe of involvement) of discontiguous, contrast enhancing disease as seen on conventional MRI
  • Known active malignancy as determined by treating medical and radiation oncologist
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring inpatient hospitalization or delay treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or compromise subject safety
  • Patients unable to undergo MRI exams
  • Patients with reproductive potential declining to use an effective contraceptive method during treatment are excluded from this study

Helyszínek itt: Egyesült Államok

  • University of Iowa Department of Radiation OncologyIowa City, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This clinical trial increases radiation to areas of the brain considered to be at risk for cancer. The at-risk areas are identified by a biological MRI scan. The study will look at side effects of the radiation and overall survival.

A vizsgálat csoportja

  • Radiation TherapyA vizsgált kezelés

    External beam radiation therapy delivered to target volume.

    Kezelés: External beam radiation therapy

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Phase II Study of High Dose Radiotherapy and Concurrent Temozolomide Using Biologically-based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma
A regiszteradat frissítve
2020. szeptember 9.